Haemorrhagic fever with renal syndrome bivalent purified vaccine (Lanzhou Institute of Biological Products)

肾综合征出血热双价纯化疫苗（Vero细胞）（兰州生物制品研究所）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHaemorrhagic fever with renal syndrome bivalent purified vaccine (Lanzhou Institute of Biological Products)
Drug Alias Name双价肾综合征出血热纯化疫苗(Vero细胞) （兰州生物制品研究所）
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHemorrhagic Fevers, Viral
Global Approved IndicationsHemorrhagic Fevers, Viral
Approved Indications in ChinaHemorrhagic Fevers, Viral
Original Approved Country/TerritoryMainland China
Original Approved Date2005/11/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLanzhou Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLanzhou Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsHemorrhagic Fevers, Viral
Inactive IndicationsN/A

Other Information

ATC CodeJ07BX
Related LinksN/A